Skip Navigation LinksHome > Advocacy > Statements


This section contains statements that have been released by AABB, its task forces or the entire blood community on issues relating to transfusion medicine and cellular therapies. Click on a link below to read current statements. For access to past statements, check our archive.


Joint Statement Before BPAC on Strategies to Control the Risk of Bacterial Contamination in Platelets for Transfusion - 7/18/2018
Statement Submitted to the Assistant Secretary for Preparedness and Response on Establishing a Public-Private Partnership - 1/10/2018


Joint Statement Before BPAC on August 2016 Zika Guidance Document – 12/1/17
Statement on Iron Management in Blood Donors - 5/17/17
Statement Before BPAC on “Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products” - 4/4/17


Joint Statement on FDA MSM Deferral Policy - 12/16/16
Statement to ACBTSA on the RAND Report Related to the Sustainability of the U.S. Blood Supply - 11/28/16
Joint Statement Before BPAC on FDA “Recommendation for Donor Screening, Deferral and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus,” August 2016 Guidance - 11/18/16
Statement Before BPAC on the Management of Iron Deficiency Associated with Blood Donation - 11/17/16
Joint Statement Addressing Outpouring of Support from Blood Donors - 6/13/16


Joint Statement on FDA Final Guidance for MSM Deferral Policy - 12/21/15
Joint Statement on Phasing-In RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential with a Serologic Weak D Phenotype - 7/22/15
Joint Statement Before TSEAC on Reconsideration of FDA’s Geographically-Based Donor Deferral Policies to Reduce the Risk of Transfusion-Transmitted vCJD - 6/1/15
Statement Before BPAC on Strategies for Implementation of Testing for Babesia microti in Blood Donors - 5/13/15
Joint Statement on FDA Draft Guidance for Deferral Criteria for MSM - 5/12/15


Joint Statement on FDA Recommendation to Change MSM Deferral Policy - 12/24/14
Statement Before BPAC on Blood Establishment Computer Software (BECS) and BECS Accessories - 12/3/14
Joint Statement on ACBTSA Recommendation to Change MSM Deferral Policy - 11/14/14
Statement to ACBTSA on Babesia Microti Testing – 11/14/14
Joint Statement Regarding Ebola and the Safety of the Blood Supply - 10/15/14
Joint Statement Regarding Reentry of Blood Donors Deferred on the Basis of Screening Test Results for Antibodies to T. cruzi - 7/31/14
Joint Statement Regarding National Gay Blood Drive - 6/26/14
Joint Statement Before BPAC on The Immucor PreciseType™ HEA Molecular BeadChip, and Similar Assays - 3/18/14
Statement Before CTGTAC on “Draft Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products” - 2/26/14


Joint Statement Before BPAC on HTLV Confirmatory Test Developed by MP Biomedicals: MP Diagnostics HTLV Blot 2.4 - 11/1/13
Joint Statement Regarding "National Gay Blood Drive" - 6/26/13


Joint Statement Before BPAC on Labeling of Red Blood Cell Units with Historical Antigen Typing Results - 12/4/12
Statement Before BPAC on Considerations for Options to Further Reduce the Risk of Bacterial Contamination in Platelets - 9/21/12
Statement on AABB’s National Blood Exchange - 8/8/12
Statement to the Radiological Devices Panel of the Medical Devices Advisory Committee - 4/12/12